A Phase 3 Study to Evaluate the Efficacy and Safety of TNX-102 SL Taken Daily in Patients With Fibromyalgia
Trial details
- Registry ID
- NCT05273749
- Drugs studied
- TNX-102 SL Tablet, 5.6 mg
TrialRedline tracks 16 clinical trials sponsored by Tonix Pharmaceuticals, Inc.: 9 Phase 3, 7 Phase 2.
Company identity has not yet been verified
Names as written in the registry records.